Clinic Roundup

• ActoGeniX NV, of Ghent, Belgium, said Phase I pharmacokinetic data for AG013, an oral rinsing solution in development for the prevention of oral mucositis, showed that the liver AG013 bacteria adhered to the buccal mucosa and actively secreted protein locally, resulting in homogenous exposure to the entire mucosal surface up to 24 hours after administration.